Hutchison MediPharma's plant-derived drug positive at Phase II for ulcerative colitis
This article was originally published in Scrip
Executive Summary
Hutchison MediPharma's Chinese herb-derived drug and lead development project, HMPL-004, has met its endpoints in a Phase IIb trial in patients with mild to moderate active ulcerative colitis, show top line data from the completed study.